TOKYO–(BUSINESS WIRE)–The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn. The decision to withdraw the BLA is based on discussions with the U
Month: September 2026
SINGAPORE–(BUSINESS WIRE)–Reference is made to the stock exchange announcement published by Hafnia Limited (“Hafnia” or the “Company”, OSE: HAFNI, NYSE: HAFN) on 24 September 2026 regarding the successful completion and pricing of an offering of 35,488,875 ordinary shares in the Company, raising gross proceeds of the NOK equivalent of approximately USD 300 million (the “Offering”). The Company has today filed a prospectus supplement pursuant to the Company’s effective shelf registration state
TORONTO–(BUSINESS WIRE)–Elmhurst® 1925, maker of the world’s finest plant-based foods and beverages, introduces Clean Protein™ in the Canadian market. The ready-to-drink plant-based protein beverage delivers 27g of complete protein with just 190 calories and absolutely no gums, seed oils, or artificial sweeteners, underscoring Elmhurst’s commitment to simple ingredients, superior performance, and the cleanest ingredient lists in an entirely new category for the brand – RTD protein. Anchoring
RESTON, Va.–(BUSINESS WIRE)– #CFCAFall2026–Communications fraud rarely stays in one lane. Bad actors move across voice, messaging, email, applications and social media – spoofing financial institutions’ phone numbers to impersonate them and defraud customers, and exploiting the fact that the intelligence needed to stop them is often scattered across platforms, companies, industries, countries and continents. The result is a widening trust gap where consumers have grown wary of even legitimate outreach from
Meeting to begin at 9 a.m. ET at 787 Seventh Avenue in New York City
THE WOODLANDS, Texas, Sept. 25, 2026 (GLOBE NEWSWIRE) — Howard Hughes Holdings Inc. (NYSE: HHH) (the “Company”) reminds shareholders and interested members of the public that its 2026 Annual Shareholder Meeting will be held Wednesday, September 30, 2026, at 9 a.m. ET at 787 Seventh Avenue in New York City.
HHH Executive Chairman Bill Ackman will be joined by HHH CEO David O’Reilly, CIO Ryan Israel, and Executive Chairman of Vantage Marc Grandisson for an update on the business and audience Q&A. Discussions will include plans to accelerate HHH’s transformation into a diversified holding company, including efforts to significantly reduce the capital intensity of Howard Hughes Communities, the Company’s real estate subsidiary, and increase capital available for investment in Vantage, the Company’s insurance subsidiary.
The meeting is open to the public, with advance registration required. Priority will be given to HHH stockholders. Only HHH stockholders of record as of August 17, 2026, will be entitled to vote at the meeting.
The 2026 Shareholder Meeting may be attended in person or via live webcast. To register and view event details, visit https://shareholdermeeting.howardhughes.com/.
About Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc. (NYSE: HHH) is a diversified holding company focused on growing long-term shareholder value. Its principal subsidiaries are Vantage Group Holdings, a leading specialty insurance, reinsurance, and partnership capital platform, and Howard Hughes Communities™, one of the nation’s leading real estate platforms. HHH brings together long-duration capital, high-quality operating businesses, and disciplined capital allocation to build long-term value. For additional information visit www.howardhughes.com.
Forward-Looking Statements
Statements made in this press release that are not historical facts, including statements accompanied by words such as “anticipate,” “will,” “believe,” “expect,” “position,” “assume,” and other words of similar expression, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s expectations, estimates, assumptions, and projections as of the date of this release and are not guarantees of future performance. Actual results may differ materially from those expressed or implied in these statements. Factors that could cause actual results to differ materially are set forth as risk factors in Howard Hughes Holdings Inc.’s filings with the Securities and Exchange Commission, including its Quarterly and Annual Reports. Howard Hughes Holdings Inc. cautions you not to place undue reliance on the forward-looking statements contained in this release. Howard Hughes Holdings Inc. does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.
Investor Relations:
investorrelations@howardhughes.com
281-929-7700
Media Relations:
press@howardhughes.com
281-929-7700
JAKARTA, INDONESIA AND DANVILLE, CA, Sept. 25, 2026 (GLOBE NEWSWIRE) — Indonesia Energy Corporation (NYSE American: INDO) (“IEC”), an oil and gas exploration and production company focused on Indonesia, today announced, in accordance with the rules of the NYSE American exchange, that it has filed its unaudited financial results for the six months ending on June 30, 2026.
More information regarding the six-month financials as well as IEC’s annual report on Form 20-F for the year ending December 31, 2025, which contains IEC’s full audited financial statements and footnotes for such year, is available on IEC’s website at: https://ir.indo-energy.com/sec-filings/.
A hard copy of IEC’s Form 20-F annual report is also available to be sent free of charge by contacting IEC at the following link: https://indo-energy.com/contact/
About Indonesia Energy Corporation Limited
Indonesia Energy Corporation Limited (NYSE American: INDO) is a publicly traded energy company engaged in the acquisition and development of strategic, high growth energy projects in Indonesia. IEC’s principal assets are its Kruh Block (63,000 acres) located onshore on the Island of Sumatra in Indonesia and its Citarum Block (195,000 acres) located onshore on the Island of Java in Indonesia. IEC is headquartered in Jakarta, Indonesia and has a representative office in Danville, California. For more information on IEC, please visit www.indo-energy.com.
Cautionary Statement Regarding Forward-Looking Statements
All statements in this press release, the live presentation described herein, and related statements of Indonesia Energy Corporation Limited (“IEC”) and its representatives and partners that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Acts”). In particular, the words “explore,” “could,” “estimates,” “seek,” “believes,” “hopes,” “understand,” “expects,” “intends,” “on-track”, “plans,” “anticipates,” “aim,” “goal,” “may” and similar conditional expressions related to the future are intended to identify forward-looking statements within the meaning of the Acts and are subject to the safe harbor created by the Acts. Any statements made in this news release, other than those of historical fact, about an action, event or development, are forward-looking statements. In this press release, forward-looking statements include, without limitation those related to the timing for, and results of, 2026 and other drilling and anticipated production activities at IEC’s Kruh Block as well as the price of oil, which changes daily and could lower over time. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of significant risks, uncertainties, and other factors, many of which are outside of the IEC’s control, that could cause actual results to materially and adversely differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth in the Risk Factors section of IEC’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed on April 29, 2026, and other filings with the Securities and Exchange Commission (SEC). Copies are of such documents are available on the SEC’s website, www.sec.gov and IEC’s website at https://ir.indo-energy.com/sec-filings/. IEC undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Company Contact:
Frank C. Ingriselli
President, Indonesia Energy Corporation Limited
Frank.Ingriselli@Indo-Energy.com
WALTHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 31,200 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on September 24, 2026 and were material to each employee’s acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options were granted with a 10-year term and an exercise price equal to $14.24, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on September 24, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contacts
Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019
LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz reminds investors of the upcoming November 16, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS) securities between August 8, 2024 and May 13, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO LOST MONEY ON DOXIMITY, INC. (DOCS), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD
WASHINGTON–(BUSINESS WIRE)– #GovWaste–CAGW Porker of the Month Sen. Sanders wants to ban the most advanced computers ever built and stop American AI development.
NEW YORK–(BUSINESS WIRE)–KKR today announced income from monetization activity in excess of $750 million with respect to the period from July 1, 2026 through September 25, 2026 based on information currently available. The quarter-to-date monetization activity is made up of approximately 80% realized performance income and approximately 20% realized investment income. The quarter-to-date monetization activity is driven by a combination of public secondary sales and strategic transactions, as